期刊文献+

托特罗定联合硝苯地平治疗女性膀胱过度活动症的疗效观察 被引量:7

Efficacy of Tolterodine combined with Nifedipine in female patients with overactive bladder
暂未订购
导出
摘要 目的探讨托特罗定联合硝苯地平治疗女性膀胱过度活动症(OAB)的疗效。方法女性OAB患者60例,随机分为2组:A组(30例,托特罗定片2 mg,2次/d,连服4周),B组(30例,托特罗定片并硝苯地平片,5 mg,3次/d,连用4周)。治疗前及结束后行ABSS评分。结果 A组患者治疗前后尿急评分分别为(3.6±1.0)与(1.8±0.5)分,OABSS评分分别为(10.9±4.8)与(5.3±1.8)分;B组患者治疗前后尿急评分分别为(3.7±0.9)与(0.8±0.1)分,OABSS评分分别为(10.8±1.8)与(3.8±1.7)分,2组治疗前后差异均有统计学意义(P<0.05),2组治疗后尿急评分和OABSS评分差异有统计学意义(P<0.05)。结论托特罗定联合硝苯地平治疗女性膀胱过度活动症效果较好。 Objective To evaluate the efficacy of Tolterodine combined with Nifedipine in female patients with overactive bladder (OAB). Methods 60 female patients with OAB were randomly divided into two groups with 30 patients. Patients in Group A received tolterodine 2 mg bid for 4 weeks. Patients in Group B received Tolterodine combined with Nifedipine 5 mg tid for 4 weeks. During the treatment all patients recorded voiding and adverse reactions in a diary. The symptoms of urgency, frequency and incontinence were evaluated with OABSS scores at the beginning and the end of the therapy period. The results of the efficacy were analyzed with SPSS 13.0. Results The OABSS scores at the beginning and the end of therapy for the two groups were significantly different (P〈0.01). The OABSS scores at the end of the therapy between the two groups were significantly different (P〈0.05). Patients in Group B had better results than patients in Group A. Conclusion Tolterodine combined with Nifedipine is more effective than Tolterodine alone in the treatment of female OAB.
出处 《现代泌尿外科杂志》 CAS 2013年第1期56-57,共2页 Journal of Modern Urology
关键词 托特罗定 硝苯地平 膀胱过度活动症 Tolterodine Nifedipine overactive bladder
  • 相关文献

参考文献6

  • 1SELLERS DJ,MCKAY N. Developments in pharmaeotherapy of the overactivebladder[J].Curr Opin Urol, 2007,17 (4) : 223-230.
  • 2OSAMU Y, OSAMU N, MASAYUKI T, et,al. Clinical guide- lines for overactive bladder [J].Int J Urol,2009,16: 126-142.
  • 3CHAPPLE CR, VAN KERREBROECK PE, JUNEMANN KP, et aL. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int, 2008,102 : 1128-1132.
  • 4曹文峰,陈昭颉,王庆堂.钙离子在逼尿肌收缩机制中的作用[J].国外医学(泌尿系统分册),2004,24(3):309-311. 被引量:7
  • 5张劲松,王健.长效钙离子拮抗剂的研究进展[J].中国误诊学杂志,2007,7(3):437-439. 被引量:12
  • 6DKUI N, OKUI M, HORIE S. inprovements in overactive blad- der syndrome after poly- propylene mesh surgery for cystocele [J]. Aust N Z J Obstet Gynaecol,2009,49:226-231.

二级参考文献27

  • 1Fry CH,Wu C,Mundy AR.Bladder instability and detrusor smooth muscle function.Experiment Physiology,1999,84,161~169
  • 2Berridge MJ.Inositol trisphosphate and calcium signalling.Nature,1993,361,315~325
  • 3Stull JT,Krueger JK,Kamm KE,et al.Myosin light chain kinase.In:~
  • 4Jaggar JH,Stevenson AS and Neleson MT.Voltage-dependence of Ca2+ sparks inintact cerebral arteries.AM J Physiol,1998,274(43),C1755~61
  • 5Wu C,Kentish JC,Fry CH.Effect of pH on myofilament Ca2+-sensitivity in alpha-toxin permeabilized guinea pig detrusor muscle.J Urol,1995,154,1921~1924
  • 6Winder SJ,Allen BG,Clenent O,et al.Regulation of smooth muscle actin-myosin interaction and force by calponin,Acta Physiol Scand,1998,164,415~26
  • 7Damaser MS,Kim KB,Longhurst PA,et al.Calcium rregulation of urinary bladder function.J Urol,1997,157(2),732~738
  • 8Chambers P,Neal DE,Gillespie JI.Ryanodine receptors in human bladder smooth muscle.Exp-Physiol,1999,84(1),41~46
  • 9Wu C,Sui G,Fry CH.The role of the L-type Ca2+ channel in refilling functional intracellular Ca2+ stores in guinea-pig detrusor smooth muscle.J Physiol,2002,538(Pt 2),357~369
  • 10Sui GP,Wu C,Fry CH.The electrophysiological properties of cultured and freshly isolated detrusor smooth muscle cells.J Urol,2001,165,627~632

共引文献16

同被引文献51

  • 1杨尚琪,来永庆,陈月英,池泽湃,任瑞,王亚东,魏灿,倪梁朝,关志忱.膀胱过度活动症症状评分表评估膀胱过度活动症的临床研究[J].中华临床医师杂志(电子版),2012,6(16):4675-4678. 被引量:26
  • 2那彦群,叶章群,孙光.中国泌尿外科疾病诊断指南[M].北京:人民卫生出版社,2011:128-130.
  • 3Abrams P, Cardozo L, Fall M, et al. The Standardisation of Terminolo- gy in Lower Urinary Tract Function: Report from the Standardisation Sub - Committee of the International Continence Society [ J ]. Urology, 2003, 61 ( 1 ) : 37 - 49.
  • 4Wein AJ, Raekley RR. overactive bladder: a better understanding of pathophysiology, diagnosis and management [ J]. Urol, 2006, 175 (3): 5 -10.
  • 5Abrams P, Andemson KE. Muscarinic receptor antagoninsts for overac- tiive bladder[ J]. BJU lnt ,2007,100(5 ) :987 - 1006.
  • 6许克新.中国地区膀胱过度活动症流行病学调查[A].第十七届全国泌尿外科学术会议论文汇编[c],2010.
  • 7那彦群.中国泌尿外科疾病诊断指南[M].2011版.北京:人民卫生出版社.2011:10.
  • 8Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for over- active bladder syndrome -overactive bladder symptom score[ J ]. Urolo- gy,2006(68) : 318 -323.
  • 9Abrams P, Andemson KE. Muscarinic receptor antagoninsts for overac- tiive bladder[ J]. BJU Int,2007,100(5 ) :987 - 1006.
  • 10Llado X, Oliver A, Cabezas M,et al. Segmentation of multi- ple sclerosis lesions in brain MR1: A review of automated ap- proaches[J]. Information Sciences,2012,186(1 ) :164 - 185.

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部